Market Cap 2.56B
Revenue (ttm) 0.00
Net Income (ttm) -175.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1,175.52
Profit Margin 0.00%
Debt to Equity Ratio 0.10
Volume 1,429,176
Avg Vol 2,243,716
Day's Range N/A - N/A
Shares Out 53.71M
Stochastic %K 20%
Beta -2.92
Analysts Strong Sell
Price Target $117.36

Company Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was i...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 213 8444
Fax: 650 213 8383
Website: soleno.life
Address:
100 Marine Parkway, Suite 400, Redwood City, United States
Quantumup
Quantumup Nov. 14 at 1:37 PM
Stifel reiterated $AARD Buy-$24 $SLNO $RYTM Stifel said: Most important to the stock, ARD-101's registrational ph3 HERO RCT in PWS remains on track with topline data anticipated in 3Q26. As outlined in our recent initiation (LINK), we continue to think there's an interesting risk/ reward into data with: (1) a ph2 clinical signal (looks similar to Vykat/beyond typical placebo); (2) an interesting biological/mechanistic story; and (3) a smart ph3 trial design that should help optimize the POS. Elsewhere, Aardvark continues to progress ARD-201 in obesity -- last week they presented interesting/supportive preclinical data across multiple relevant/predictive animal models (LINK). Initial ph2 POWER weight-maintenance data are expected 2H26 where, with no credit today (and significant investor/strategic interest in the space), we think there's interesting optionality for the stock. We also just hosted Aardvark at our healthcare conference, where we discussed ARD-101 and ARD-201 in much more detail.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 5:16 AM
$SLNO: The last close at $47.35 indicates a significant decline from the 60D high of $72.99, positioning the stock closer to its 60D low of $41.8. The RSI at 29.71 suggests the stock is oversold, indicating potential for a rebound. However, the moving averages (MA30 at 60.95 and MA50 at 60.67) are both above the current price, signaling a bearish trend in the short to medium term. Directional bias is cautiously bullish due to the oversold RSI, but the prevailing trend remains bearish as indicated by the moving averages. Suggested entry: $48.50, above the last close, to confirm upward momentum. Stop loss: $46.00, to limit potential losses below recent support levels. Targets: $52.00 (first target, a resistance level) and $55.00 (second target, near the MA50). Monitor market conditions closely for volatility, given the ATR of 4.94. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 3:22 AM
$SLNO: The current market context shows a last close of $48.7, significantly below both the 30-day (61.71) and 50-day (61.5) moving averages, indicating a bearish trend. The RSI at 29.26 suggests that the stock is oversold, which could lead to a potential reversal or bounce. However, the price is still within the 60-day high-low range (41.8 - 72.99), providing a context for possible upward movement. Directional bias leans bearish due to the proximity to the low end of the range and the declining moving averages. Suggested entry point: $49.00, just above the last close to confirm momentum. Stop loss: $46.50, below recent support levels. Targets: $54.00 (near the 30-day MA) and $58.00 (mid-range target). Monitor for any signs of reversal as the RSI approaches oversold levels. https://privateprofiteers.com
0 · Reply
jw56502
jw56502 Nov. 12 at 4:25 PM
$SLNO CEOs Comments from Stifel: 1. 100m buy back because we are UNDERVALUED. 2. We expect smooth net patient adds over 12 months. 3. We have 10% of Market now and will be 20% next year EOY. 4. KOLs will prescribe in normal cadence in big practices going forward (they see patients 2 times a year). 5. Numerous stories about positive efficacy in early treatment. 6. Coverage is solid. 7. EU is ca. 10k patients approval May26. 8. EU, "there is a lot of interest in partnering", we have enough cash if we want to launch ourselves. "We will make a decision in the relative short future". This is not the same CEO on the CC, the only weapon shorts had was the element of surprise, not any longer :). Other than lurking like leeches in a Facebook group, they have nothing else....GL
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 12 at 3:18 PM
$SLNO I could see Scorpion swing back and try to manipulate the stock down below $45/. They won't be thwarted by the buyback. GLTA
0 · Reply
FinleyBuchananLoom
FinleyBuchananLoom Nov. 12 at 11:05 AM
$SLNO biotech to
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:58 AM
$SLNO: The current market context shows a last close of $48.7, significantly below both the 30-day (61.71) and 50-day (61.5) moving averages, indicating a bearish trend. The RSI at 29.26 suggests that the stock is oversold, which could lead to a potential reversal or bounce. However, the price is still within the 60-day high-low range (41.8 - 72.99), providing a context for possible upward movement. Directional bias leans bearish due to the proximity to the low end of the range and the declining moving averages. Suggested entry point: $49.00, just above the last close to confirm momentum. Stop loss: $46.50, below recent support levels. Targets: $54.00 (near the 30-day MA) and $58.00 (mid-range target). Monitor for any signs of reversal as the RSI approaches oversold levels. https://privateprofiteers.com
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Nov. 11 at 8:13 PM
$SLNO Already starting buybacks just after launch, up from here. Back to 70s before eoy
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 11 at 2:15 PM
$SLNO Smart-- they sold stock at $85/ in July. When the short story fades and the stock recovers they can once again sell shares into the market at higher prices. Scorpion is underwater in their TMDX short, if they are actually going short. Looking to buy on weakness...if it pulls back. GLTA
0 · Reply
Quantumup
Quantumup Nov. 11 at 2:04 PM
H.C. Wainwright reiterated $DRUG Buy/$85 $SLNO $RYTM $AARD LBPH - $HLUBF/ HLBBF H.C. Wainwright said in its note:
0 · Reply
Latest News on SLNO
Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm

Nov 12, 2025, 10:56 AM EST - 2 days ago

Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm


Soleno: Blockbuster Launch In Progress

Oct 11, 2025, 8:45 AM EDT - 4 weeks ago

Soleno: Blockbuster Launch In Progress


Soleno Therapeutics Announces VYKAT(TM) XR Launch

Apr 14, 2025, 7:00 AM EDT - 7 months ago

Soleno Therapeutics Announces VYKAT(TM) XR Launch


Quantumup
Quantumup Nov. 14 at 1:37 PM
Stifel reiterated $AARD Buy-$24 $SLNO $RYTM Stifel said: Most important to the stock, ARD-101's registrational ph3 HERO RCT in PWS remains on track with topline data anticipated in 3Q26. As outlined in our recent initiation (LINK), we continue to think there's an interesting risk/ reward into data with: (1) a ph2 clinical signal (looks similar to Vykat/beyond typical placebo); (2) an interesting biological/mechanistic story; and (3) a smart ph3 trial design that should help optimize the POS. Elsewhere, Aardvark continues to progress ARD-201 in obesity -- last week they presented interesting/supportive preclinical data across multiple relevant/predictive animal models (LINK). Initial ph2 POWER weight-maintenance data are expected 2H26 where, with no credit today (and significant investor/strategic interest in the space), we think there's interesting optionality for the stock. We also just hosted Aardvark at our healthcare conference, where we discussed ARD-101 and ARD-201 in much more detail.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 5:16 AM
$SLNO: The last close at $47.35 indicates a significant decline from the 60D high of $72.99, positioning the stock closer to its 60D low of $41.8. The RSI at 29.71 suggests the stock is oversold, indicating potential for a rebound. However, the moving averages (MA30 at 60.95 and MA50 at 60.67) are both above the current price, signaling a bearish trend in the short to medium term. Directional bias is cautiously bullish due to the oversold RSI, but the prevailing trend remains bearish as indicated by the moving averages. Suggested entry: $48.50, above the last close, to confirm upward momentum. Stop loss: $46.00, to limit potential losses below recent support levels. Targets: $52.00 (first target, a resistance level) and $55.00 (second target, near the MA50). Monitor market conditions closely for volatility, given the ATR of 4.94. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 3:22 AM
$SLNO: The current market context shows a last close of $48.7, significantly below both the 30-day (61.71) and 50-day (61.5) moving averages, indicating a bearish trend. The RSI at 29.26 suggests that the stock is oversold, which could lead to a potential reversal or bounce. However, the price is still within the 60-day high-low range (41.8 - 72.99), providing a context for possible upward movement. Directional bias leans bearish due to the proximity to the low end of the range and the declining moving averages. Suggested entry point: $49.00, just above the last close to confirm momentum. Stop loss: $46.50, below recent support levels. Targets: $54.00 (near the 30-day MA) and $58.00 (mid-range target). Monitor for any signs of reversal as the RSI approaches oversold levels. https://privateprofiteers.com
0 · Reply
jw56502
jw56502 Nov. 12 at 4:25 PM
$SLNO CEOs Comments from Stifel: 1. 100m buy back because we are UNDERVALUED. 2. We expect smooth net patient adds over 12 months. 3. We have 10% of Market now and will be 20% next year EOY. 4. KOLs will prescribe in normal cadence in big practices going forward (they see patients 2 times a year). 5. Numerous stories about positive efficacy in early treatment. 6. Coverage is solid. 7. EU is ca. 10k patients approval May26. 8. EU, "there is a lot of interest in partnering", we have enough cash if we want to launch ourselves. "We will make a decision in the relative short future". This is not the same CEO on the CC, the only weapon shorts had was the element of surprise, not any longer :). Other than lurking like leeches in a Facebook group, they have nothing else....GL
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 12 at 3:18 PM
$SLNO I could see Scorpion swing back and try to manipulate the stock down below $45/. They won't be thwarted by the buyback. GLTA
0 · Reply
FinleyBuchananLoom
FinleyBuchananLoom Nov. 12 at 11:05 AM
$SLNO biotech to
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:58 AM
$SLNO: The current market context shows a last close of $48.7, significantly below both the 30-day (61.71) and 50-day (61.5) moving averages, indicating a bearish trend. The RSI at 29.26 suggests that the stock is oversold, which could lead to a potential reversal or bounce. However, the price is still within the 60-day high-low range (41.8 - 72.99), providing a context for possible upward movement. Directional bias leans bearish due to the proximity to the low end of the range and the declining moving averages. Suggested entry point: $49.00, just above the last close to confirm momentum. Stop loss: $46.50, below recent support levels. Targets: $54.00 (near the 30-day MA) and $58.00 (mid-range target). Monitor for any signs of reversal as the RSI approaches oversold levels. https://privateprofiteers.com
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Nov. 11 at 8:13 PM
$SLNO Already starting buybacks just after launch, up from here. Back to 70s before eoy
0 · Reply
Tdorsey1776
Tdorsey1776 Nov. 11 at 2:15 PM
$SLNO Smart-- they sold stock at $85/ in July. When the short story fades and the stock recovers they can once again sell shares into the market at higher prices. Scorpion is underwater in their TMDX short, if they are actually going short. Looking to buy on weakness...if it pulls back. GLTA
0 · Reply
Quantumup
Quantumup Nov. 11 at 2:04 PM
H.C. Wainwright reiterated $DRUG Buy/$85 $SLNO $RYTM $AARD LBPH - $HLUBF/ HLBBF H.C. Wainwright said in its note:
0 · Reply
DonCorleone77
DonCorleone77 Nov. 11 at 1:48 PM
$SLNO Soleno board authorizes $100M Accelerated Share Repurchase Agreement
0 · Reply
topstockalerts
topstockalerts Nov. 11 at 1:35 PM
Shares of Soleno Therapeutics rose after the biopharmaceutical company announced a $100 million accelerated share repurchase agreement with Jefferies LLC. The board authorized the buyback program, which includes an initial delivery of approximately 1,511,553 shares based on Soleno’s closing price on November 10, 2025. The final number of shares repurchased will be determined by the volume-weighted average price of Soleno’s common stock during the transaction period, expected to conclude in the first quarter of 2026. “These actions reflect our confidence in our commercial launch and the compelling opportunity for VYKAT XR to become a foundational therapy for patients with hyperphagia associated with Prader-Willi syndrome,” said Dr. Anish Bhatnagar, CEO and Chairman of Soleno Therapeutics. $SLNO
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 11 at 1:17 PM
$SLNO (+8.4% pre) Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement https://ooc.bz/l/84028
0 · Reply
jw56502
jw56502 Nov. 11 at 1:11 PM
$SLNO 100m accelerated share repurchase is OK, I would have expected the board to lay the hammer down wit 300-500m over X years. Now Management NEEDS to start selling the OUS market...next up partner in Asia and increase selling the story of the company and run the shorts over....
0 · Reply
RonIsWrong
RonIsWrong Nov. 11 at 12:27 PM
$SLNO Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement
0 · Reply
MaryBianchi
MaryBianchi Nov. 11 at 12:06 PM
📢Breaking News: $SLNO Soleno Therapeutics has reached a $100 million stock buyback agreement.
0 · Reply
MABA1
MABA1 Nov. 11 at 12:05 PM
$SLNO got in at 45 usd, seems to be spiking pre market
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 10 at 8:50 PM
$SLNO Share Price: $46.51 Contract Selected: Mar 20, 2026 $45 Calls Buy Zone: $9.27 – $11.45 Target Zone: $16.58 – $20.26 Potential Upside: 69% ROI Time to Expiration: 129 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
jw56502
jw56502 Nov. 9 at 9:59 AM
$SLNO The Board needs to come in and defend its shareholders and Management needs to handle the cc better (stop being reactive and get proactive): 1. They should have announced to the market a 3-500m buyback program over x years. 2. They need to "sell" the market proposition/TAM in the US AND the next mid term triggers (EU and Asia). 3. Stop addressing shorts, period and run them over with FACTS and profitability. They have 500m on the books and are already profitable from last quarter. They can still look to allocate to increase the pipeline, although at current valuation, they would look better in a big pharmas portfolio vs. go it alone.
0 · Reply
Popsnap
Popsnap Nov. 7 at 8:15 PM
$SLNO Solid bounce today after that earnings call debacle!
0 · Reply
Quantumup
Quantumup Nov. 7 at 7:24 PM
Goldman Sachs trimmed⬇️ $RYTM's PT to $141 from $142/keeps at a Buy rating. $LLY $SLNO $AARD Here's what Goldman Sachs had to say:
0 · Reply
Quantumup
Quantumup Nov. 7 at 12:11 PM
BTIG🏁 $AARD at a Buy rating and a $26 PT. $SLNO $RYTM $LLY $NVO VKTX BTIG in its initiation report said: Aardvark Therapeutics is a clinical stage biopharmaceutical company developing ARD-101, a TAS2R agonist for Prader Willi Syndrome (PWS), and ARD-201 for weight loss and weight rebound prevention. The ph 3 HERO trial of ARD-101 is ongoing in PWS patients, with topline data expected in 3Q26. We expect data from the phase 2 POWER (weight maintenance) trial in 2H26 and start of the STRENGTH trial (weight loss) in 1H26. We believe '101's excellent safety profile and differentiated mechanism are underappreciated by the Street, but the real upside comes from '201 and the opportunity to prevent weight regain from GLP-1 discontinuations or to tack on additional weight loss on top of a GLP-1RA. We believe the current valuation, coupled with unmet needs in the PWS and obesity markets, provide a positive set up to shares over the next 12 mos. Initiate at Buy and $26PT.
0 · Reply